Opinion

Video

Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.

  1. Can you discuss some of the exploratory treatments for BCG‐unresponsive intermediate and high risk‐NMIBC? (eg. immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators)
  2. BCG‐unresponsiveness (definition?)
    1. Include (recently) approved immunotherapies: pembrolizumab, nogapendekin alfa inbakicept-pmln
  3. Gene therapy: nadofaragene firadenovec
Related Videos
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
1 expert in this video
4 experts in this video
© 2025 MJH Life Sciences

All rights reserved.